A paper published in The Journal for Molecular Diagnostics shows a direct comparison between the Archer FusionPlex Sarcoma panel and conventional methods for gene fusion detection, including fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR)
The Archer® VariantPlex® p53 Kit combines superior TP53 gene coverage with robust enrichment chemistry and an easy-to-use workflow to give you confident, sensitive and quantitative TP53 variant calling.
CEBPA mutations are important prognostic indicators in AML, however detecting CEBPA mutations by NGS is challenging due to high GC content. Here, we show that AMP-based NGS provides superior coverage of CEBPA and we demonstrate the use of normalization datasets to assess the noise at each base position to calculate the per-base variant detection sensitivity across CEBPA, expressed as 95 MDAF.
Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).
Cancer is caused by mutations in specific genes. Many of these genes, including ALK, RET and ROS1, are called driver oncogenes because they are critical to the survival, growth and proliferation of cancer cells
For Research Use Only. Not for use in diagnostic procedures.
Having trouble getting the documents using Chrome Browser? Make sure you're using the default zoom factor by pressing Control + 0 on a PC or Command + 0 on a Mac. Hover over the PDF in this window and the download button should appear in a black bar at the top.